Design Therapeutics (DSGN) Amortization of Deferred Charges (2020)
Design Therapeutics recorded quarterly Amortization of Deferred Charges of $12000.0 in Q1 2020.
Design Therapeutics' Amortization of Deferred Charges history runs 1 years deep, the most recent figure standing at $12000.0 for Q1 2020.
- In Q1 2020, Amortization of Deferred Charges changed N/A year-over-year to $12000.0; the TTM figure through Dec 2020 stood at $12000.0 (changed N/A YoY), while the FY2020 annual figure was $12000.0, changed N/A from the prior year.
- Amortization of Deferred Charges came in at $12000.0 for Q1 2020 at Design Therapeutics.
- In the past five years, Amortization of Deferred Charges ranged from a high of $12000.0 in Q1 2020 to a low of $12000.0 in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 12,000.00 |
| Mar 31, 2020 | 12,000.00 |